AIM ImmunoTech Inc. (AIM)
USD 0.2
(-6.89%)
USD 0.2
(-6.89%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 495 Thousand USD | -14.22% |
| 2022 | 837 Thousand USD | 461.74% |
| 2021 | 149 Thousand USD | -93.48% |
| 2020 | 2.28 Million USD | -64.18% |
| 2019 | 6.38 Million USD | 7.68% |
| 2018 | 5.92 Million USD | 222.89% |
| 2017 | 1.83 Million USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 1000.00 USD | -95.45% |
| 2014 | 22 Thousand USD | -60.71% |
| 2013 | 56 Thousand USD | -44.55% |
| 2012 | 101 Thousand USD | -95.46% |
| 2011 | 2.22 Million USD | 1315.92% |
| 2010 | 157 Thousand USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 3.87 Million USD | 20.33% |
| 2005 | 3.21 Million USD | -9.46% |
| 2004 | 3.55 Million USD | 72.64% |
| 2003 | 2.05 Million USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | -100.0% |
| 1995 | 4.9 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 3.35 Million USD | 366.57% |
| 2024 Q2 | 3.35 Million USD | 0.27% |
| 2023 Q3 | 750 Thousand USD | -6.6% |
| 2023 FY | 718 Thousand USD | -14.22% |
| 2023 Q4 | 718 Thousand USD | -4.27% |
| 2023 Q2 | 803 Thousand USD | -1.35% |
| 2023 Q1 | 814 Thousand USD | -2.75% |
| 2022 Q1 | 144 Thousand USD | -3.36% |
| 2022 FY | 837 Thousand USD | 461.74% |
| 2022 Q4 | 837 Thousand USD | -3.35% |
| 2022 Q3 | 866 Thousand USD | -2.59% |
| 2022 Q2 | 889 Thousand USD | 517.36% |
| 2021 Q3 | 144 Thousand USD | -8.28% |
| 2021 FY | 149 Thousand USD | -93.48% |
| 2021 Q4 | 149 Thousand USD | 3.47% |
| 2021 Q1 | 2.21 Million USD | -2.93% |
| 2021 Q2 | 157 Thousand USD | -92.92% |
| 2020 Q3 | 2.34 Million USD | 0.17% |
| 2020 Q4 | 2.28 Million USD | -2.68% |
| 2020 FY | 2.28 Million USD | -64.18% |
| 2020 Q1 | 6.6 Million USD | 3.54% |
| 2020 Q2 | 2.34 Million USD | -64.52% |
| 2019 Q4 | 6.38 Million USD | -7.68% |
| 2019 FY | 6.38 Million USD | 7.68% |
| 2019 Q2 | 4.88 Million USD | -22.31% |
| 2019 Q3 | 6.91 Million USD | 41.42% |
| 2019 Q1 | 6.29 Million USD | 6.16% |
| 2018 Q3 | 5.95 Million USD | 127.91% |
| 2018 FY | 5.92 Million USD | 222.89% |
| 2018 Q4 | 5.92 Million USD | -0.47% |
| 2018 Q2 | 2.61 Million USD | -1.84% |
| 2018 Q1 | 2.66 Million USD | 45.01% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | 1.83 Million USD | 0.0% |
| 2017 Q4 | 1.83 Million USD | 25.17% |
| 2017 Q3 | 1.46 Million USD | 183.56% |
| 2017 Q2 | 517 Thousand USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | -100.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | - USD | -100.0% |
| 2015 Q1 | 15 Thousand USD | -31.82% |
| 2015 Q2 | 7000.00 USD | -53.33% |
| 2015 Q3 | 3000.00 USD | -57.14% |
| 2015 FY | 1000.00 USD | -95.45% |
| 2015 Q4 | 1000.00 USD | -66.67% |
| 2014 FY | 22 Thousand USD | -60.71% |
| 2014 Q1 | 60 Thousand USD | 7.14% |
| 2014 Q3 | 32 Thousand USD | -37.25% |
| 2014 Q4 | 22 Thousand USD | -31.25% |
| 2014 Q2 | 51 Thousand USD | -15.0% |
| 2013 Q3 | 7.18 Million USD | -0.62% |
| 2013 Q4 | 56 Thousand USD | -99.22% |
| 2013 Q1 | 7.34 Million USD | 7172.28% |
| 2013 Q2 | 7.22 Million USD | -1.61% |
| 2013 FY | 56 Thousand USD | -44.55% |
| 2012 Q2 | 4.45 Million USD | 84.83% |
| 2012 Q3 | 5.87 Million USD | 31.76% |
| 2012 FY | 101 Thousand USD | -95.46% |
| 2012 Q4 | 101 Thousand USD | -98.28% |
| 2012 Q1 | 2.41 Million USD | 8.5% |
| 2011 Q1 | 157 Thousand USD | 0.0% |
| 2011 FY | 2.22 Million USD | 1315.92% |
| 2011 Q3 | 169 Thousand USD | -10.11% |
| 2011 Q2 | 188 Thousand USD | 19.75% |
| 2011 Q4 | 2.22 Million USD | 1215.38% |
| 2010 Q1 | 65 Thousand USD | 0.0% |
| 2010 Q2 | 56 Thousand USD | -13.85% |
| 2010 Q4 | 157 Thousand USD | -9.25% |
| 2010 FY | 157 Thousand USD | 0.0% |
| 2010 Q3 | 173 Thousand USD | 208.93% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 FY | - USD | -100.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | 3.98 Million USD | 3.0% |
| 2007 Q2 | - USD | -100.0% |
| 2006 FY | 3.87 Million USD | 20.33% |
| 2006 Q1 | 3.52 Million USD | 9.54% |
| 2006 Q4 | 3.87 Million USD | 3.06% |
| 2006 Q2 | 3.64 Million USD | 3.29% |
| 2006 Q3 | 3.75 Million USD | 3.19% |
| 2005 Q2 | 4.65 Million USD | 10.37% |
| 2005 FY | 3.21 Million USD | -9.46% |
| 2005 Q1 | 4.21 Million USD | 18.63% |
| 2005 Q4 | 3.21 Million USD | -34.89% |
| 2005 Q3 | 4.94 Million USD | 6.21% |
| 2004 Q1 | 2.58 Million USD | 25.66% |
| 2004 Q4 | 3.55 Million USD | 24.36% |
| 2004 Q3 | 2.85 Million USD | -10.3% |
| 2004 Q2 | 3.18 Million USD | 23.16% |
| 2004 FY | 3.55 Million USD | 72.64% |
| 2003 Q4 | 2.05 Million USD | 56.15% |
| 2003 Q3 | 1.31 Million USD | 0.0% |
| 2003 FY | 2.05 Million USD | 0.0% |
| 2003 Q1 | 1.2 Million USD | 0.0% |
| 2003 Q2 | - USD | -100.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 FY | - USD | -100.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | -100.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1995 Q4 | 4.9 Million USD | 0.0% |
| 1995 FY | 4.9 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -80.657% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 99.589% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | 76.574% |
| Azitra, Inc. | 885.94 Thousand USD | 44.128% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -1137.531% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | 60.983% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | 93.159% |
| CEL-SCI Corporation | 13.57 Million USD | 96.353% |
| iBio, Inc. | 4.46 Million USD | 88.901% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | 83.232% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | 86.08% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | 79.666% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | 81.934% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | -58.297% |
| BiomX Inc. | 15.09 Million USD | 96.72% |
| BiomX Inc. | 15.09 Million USD | 96.72% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | 98.117% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | 16.15% |
| Scorpius Holdings, Inc. | 14.04 Million USD | 96.475% |